Alternative consent methods used in the multinational, pragmatic, randomised clinical trial SafeBoosC-III

Maria Linander Vestager,Mathias Lühr Hansen,Gorm Greisen,Adelina Pellicer,Caitriona Ni Chathasaigh,Chantal Lecart,Claudia Knoepfli,Cornelia Hagmann,Dario Gallo,Ebru Ergenekon,Eleftheria Hatzidaki,Eugene Dempsey,Evangelina Papathoma,Gabriel Dimitrou,Gerhard Pichler,Gitte Holst Hahn,Gunnar Naulaers,Hans Fuchs,Hilal Ozkan,Isabel de las Cuevas,Itziar Serrano-Viñuales,Jan Sirc,Julie de Buyst,Kosmos Sarafidis,Luis Arrusa,Mariana Baserga,Martin Stocker,Merih Cetinkaya,Miguel Alsina,Monica Fumagalli,Olalla Otero Vaccarello,Olivier Baud,Pamela Zafra-Rodríguez,Pierre Maton,Quoqiang Cheng,Ruth del Rio Florentino,Ryszard Lauterbach,Salvador Piris-Borregas,Saudamini Nesargi,Siv Fredly,Sylwia Marciniak,Tomasz Szczapa,Xiaoyang Gao,Xin Xu,the SafeBoosC-III trial group
DOI: https://doi.org/10.1186/s13063-024-08074-0
IF: 2.728
2024-04-06
Trials
Abstract:The process of obtaining prior informed consent for experimental treatment does not fit well into the clinical reality of acute and intensive care. The therapeutic window of interventions is often short, which may reduce the validity of the consent and the rate of enrolled participants, to delay trial completion and reduce the external validity of the results. Deferred consent and 'opt-out' are alternative consent methods. The SafeBoosC-III trial was a randomised clinical trial investigating the benefits and harms of cerebral oximetry monitoring in extremely preterm infants during the first 3 days after birth, starting within the first 6 h after birth. Prior, deferred and opt-out consent were all allowed by protocol.
medicine, research & experimental
What problem does this paper attempt to address?